{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:55:03Z","timestamp":1791467703349,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-026-08386-2","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:12:16Z","timestamp":1783937536000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cumulative anticholinergic burden is associated with lower clozapine metabolic ratios: a cross-sectional study"],"prefix":"10.1186","volume":"26","author":[{"given":"Sel\u00e7uk","family":"\u00d6zdin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6mer","family":"B\u00f6ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"8386_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/bs.apha.2017.09.009","volume":"82","author":"JY Khokhar","year":"2018","unstructured":"Khokhar JY, Henricks AM, Sullivan ED, Green AI. Unique effects of clozapine: a pharmacological perspective. Adv Pharmacol. 2018;82:137\u201362.","journal-title":"Adv Pharmacol"},{"issue":"suppl 8","key":"8386_CR2","first-page":"18308","volume":"61","author":"DD Miller","year":"2000","unstructured":"Miller DD. Review and management of clozapine side effects. J Clin Psychiatry. 2000;61(suppl 8):18308.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"8386_CR3","doi-asserted-by":"publisher","first-page":"e12384","DOI":"10.1111\/appy.12384","volume":"12","author":"J de Leon","year":"2020","unstructured":"de Leon J, Schoretsanitis G, Kane JM, Ruan C-J. Using therapeutic drug monitoring to personalize clozapine dosing in Asians. Asia-Pacific Psychiatry. 2020;12(2):e12384.","journal-title":"Asia-Pacific Psychiatry"},{"issue":"4","key":"8386_CR4","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/FTD.0b013e3181dad1fb","volume":"32","author":"L Couchman","year":"2010","unstructured":"Couchman L, Morgan PE, Spencer EP, Flanagan RJ. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993\u20132007. Ther Drug Monit. 2010;32(4):438\u201347.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"8386_CR5","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1186\/s12888-023-05078-z","volume":"23","author":"T Liu","year":"2023","unstructured":"Liu T, Gao P, Xie C, Zhang H, Shi Z, Chen R. Study on the daily dose and serum concentration of clozapine in psychiatric patients and possible influencing factors of serum concentration. BMC Psychiatry. 2023;23(1):596.","journal-title":"BMC Psychiatry"},{"issue":"6","key":"8386_CR6","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/ph14060514","volume":"14","author":"N Moschny","year":"2021","unstructured":"Moschny N, Hefner G, Grohmann R, Eckermann G, Maier HB, Seifert J, et al. Therapeutic Drug Monitoring of Second- and Third-Generation Antipsychotic Drugs\u2014Influence of Smoking Behavior and Inflammation on Pharmacokinetics. Pharmaceuticals. 2021;14(6):514.","journal-title":"Pharmaceuticals"},{"issue":"2","key":"8386_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/JCP.0000000000001018","volume":"39","author":"C-J Ruan","year":"2019","unstructured":"Ruan C-J, Zang Y-N, Wang C-Y, Cheng Y-H, Sun C, Spina E, et al. Clozapine Metabolism in East Asians and Caucasians: A Pilot Exploration of the Prevalence of Poor Metabolizers and a Systematic Review. J Clin Psychopharmacol. 2019;39(2):135\u201344.","journal-title":"J Clin Psychopharmacol"},{"key":"8386_CR8","doi-asserted-by":"crossref","unstructured":"Espnes KA, Spigset O, Bratt GE, Tilrem M, Hamnes S, Skogvoll E, et al. Association Between Levels of the Acute Phase Proteins Alpha-1-Acid Glycoprotein and C-Reactive Protein and Serum Concentrations of Clozapine: A Study of 1106 Therapeutic Drug Monitoring Samples. Basic Clin Pharmacol Toxicol. 2026;138(3):e70208.","DOI":"10.1111\/bcpt.70208"},{"issue":"1","key":"8386_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/acps.13801","volume":"152","author":"RL Smith","year":"2025","unstructured":"Smith RL, Andreassen OA, Kane JM, Schoretsanitis G, Molden E. Correlation Between Clozapine and CRP Levels in Relation to Smoking Status. Acta psychiatrica Scandinavica. 2025;152(1):69\u201376.","journal-title":"Acta psychiatrica Scandinavica"},{"key":"8386_CR10","doi-asserted-by":"publisher","first-page":"116684","DOI":"10.1016\/j.psychres.2025.116684","volume":"352","author":"N Preobrazenski","year":"2025","unstructured":"Preobrazenski N, Hsieh T, Robertson C, Thai H, Owoeye O. Polypharmacy in clozapine-treated patients: A retrospective analysis of 667 patients in Ottawa, Canada. Psychiatry Res. 2025;352:116684.","journal-title":"Psychiatry Res"},{"key":"8386_CR11","first-page":"1999","volume":"29","author":"KL Ord","year":"2023","unstructured":"Ord KL, Marais B. Clozapine use at a specialised psychiatric hospital in Johannesburg. South Afr J psychiatry: SAJP: J Soc Psychiatrists South Afr. 2023;29:1999.","journal-title":"South Afr J psychiatry: SAJP: J Soc Psychiatrists South Afr"},{"issue":"2","key":"8386_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/JCP.0000000000001348","volume":"41","author":"S Grover","year":"2021","unstructured":"Grover S, Naskar C, Chakrabarti S. Does the Starting of Clozapine Influence Coprescription of Other Medications? A Study From India. J Clin Psychopharmacol. 2021;41(2):148\u201354.","journal-title":"J Clin Psychopharmacol"},{"key":"8386_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.schres.2017.03.034","volume":"190","author":"S Eum","year":"2017","unstructured":"Eum S, Hill SK, Rubin LH, Carnahan RM, Reilly JL, Ivleva EI, et al. Cognitive burden of anticholinergic medications in psychotic disorders. Schizophr Res. 2017;190:129\u201335.","journal-title":"Schizophr Res"},{"key":"8386_CR14","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.schres.2024.01.020","volume":"264","author":"V Peralta","year":"2024","unstructured":"Peralta V, de Jal\u00f3n EG, Moreno-Izco L, Peralta D, Janda L, S\u00e1nchez-Torres AM, et al. The effect of anticholinergic burden of psychiatric medications on major outcome domains of psychotic disorders: A 21-year prospective cohort study. Schizophr Res. 2024;264:386\u201393.","journal-title":"Schizophr Res"},{"issue":"Suppl 1","key":"8386_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/ggi.14706","volume":"24","author":"S Yamada","year":"2024","unstructured":"Yamada S, Mochizuki M, Atobe K, Kato Y. Pharmcokinetic and pharmacodynamic considerations for the anticholinergic burden scale of drugs. Geriatr Gerontol Int. 2024;24(Suppl 1):81\u20137.","journal-title":"Geriatr Gerontol Int"},{"key":"8386_CR16","unstructured":"King R, Rabino S. Available from: https:\/\/www.acbcalc.com\/."},{"issue":"3","key":"8386_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2217\/1745509X.4.3.311","volume":"4","author":"M Boustani","year":"2008","unstructured":"Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of Anticholinergics on the Aging Brain: A Review and Practical Application. Aging Health. 2008;4(3):311\u201320.","journal-title":"Aging Health"},{"issue":"1","key":"8386_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12877-018-0929-6","volume":"18","author":"EK Kiesel","year":"2018","unstructured":"Kiesel EK, Hopf YM, Drey M. An anticholinergic burden score for German prescribers: score development. BMC Geriatr. 2018;18(1):239.","journal-title":"BMC Geriatr"},{"key":"8386_CR19","doi-asserted-by":"publisher","first-page":"1505007","DOI":"10.3389\/fmed.2025.1505007","volume":"12","author":"S Pistorio","year":"2025","unstructured":"Pistorio S, Scotto di Tella G, Canzanella V, Merenda R, Cuomo G, Iacotucci P, et al. Anticholinergic burden and behavioral and psychological symptoms in older patients with cognitive impairment. Front Med. 2025;12:1505007.","journal-title":"Front Med"},{"issue":"1","key":"8386_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13104-016-2335-5","volume":"10","author":"P Forget","year":"2017","unstructured":"Forget P, Khalifa C, Defour JP, Latinne D, Van Pel MC, De Kock M. What is the normal value of the neutrophil-to-lymphocyte ratio? BMC Res Notes. 2017;10(1):12.","journal-title":"BMC Res Notes"},{"issue":"2","key":"8386_CR21","doi-asserted-by":"publisher","first-page":"45450","DOI":"10.31083\/AP45450","volume":"27","author":"P G\u00f6ksel","year":"2026","unstructured":"G\u00f6ksel P, \u00d6zdin S. Complete Blood-Count-Derived Inflammatory Markers Across Acute Mood Episodes. Alpha Psychiatry. 2026;27(2):45450.","journal-title":"Alpha Psychiatry"},{"issue":"1","key":"8386_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s40495-025-00425-y","volume":"11","author":"A Ruiz","year":"2025","unstructured":"Ruiz A, DiCristina S. Absorption to Excretion: The Aging Body\u2019s Take on Drugs \u2013 A Review of Pharmacokinetic Changes and their Impact on Medication Management. Curr Pharmacol Rep. 2025;11(1):42.","journal-title":"Curr Pharmacol Rep"},{"key":"8386_CR23","doi-asserted-by":"publisher","first-page":"100317","DOI":"10.1016\/j.scog.2024.100317","volume":"37","author":"C Mart\u00ednez-Cao","year":"2024","unstructured":"Mart\u00ednez-Cao C, Garc\u00eda-Fern\u00e1ndez A, Gonz\u00e1lez-Blanco L, S\u00e1iz PA, Bobes J, Garc\u00eda-Portilla MP. Anticholinergic load: A commonly neglected and preventable risk to cognition during schizophrenia treatment? Schizophrenia Res Cognition. 2024;37:100317.","journal-title":"Schizophrenia Res Cognition"},{"issue":"9","key":"8386_CR24","doi-asserted-by":"publisher","first-page":"e1284","DOI":"10.4088\/JCP.17m11523","volume":"78","author":"C Tsoutsoulas","year":"2017","unstructured":"Tsoutsoulas C, Mulsant BH, Kumar S, Ghazala Z, Voineskos AN, Menon M, et al. Anticholinergic Burden and Cognition in Older Patients With Schizophrenia. J Clin Psychiatry. 2017;78(9):e1284\u201390.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"8386_CR25","first-page":"139","volume":"8","author":"SK Okudur","year":"2021","unstructured":"Okudur SK, Dokuzlar O, Aydin AE, Kocyigit SE, Soysal P, Isik AT. The evaluation of relationship between polypharmacy and anticholinergic burden scales. North Clin Istanb. 2021;8(2):139\u201344.","journal-title":"North Clin Istanb"},{"key":"8386_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12877-015-0029-9","volume":"15","author":"MS Salahudeen","year":"2015","unstructured":"Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 2015;15:31.","journal-title":"BMC Geriatr"},{"issue":"7","key":"8386_CR27","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/s00406-022-01542-1","volume":"273","author":"N Kuzo","year":"2023","unstructured":"Kuzo N, Haen E, Ho DM, Takeuchi H, Piras M, Eap C-B, et al. Clozapine once- versus multiple-daily dosing: a two-center cross-sectional study, systematic review and meta-analysis. Eur Arch Psychiatry Clin NeuroSci. 2023;273(7):1567\u201378.","journal-title":"Eur Arch Psychiatry Clin NeuroSci"},{"issue":"6","key":"8386_CR28","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/acps.13228","volume":"142","author":"E Wagner","year":"2020","unstructured":"Wagner E, McMahon L, Falkai P, Hasan A, Siskind D. Impact of smoking behavior on clozapine blood levels - a systematic review and meta-analysis. Acta psychiatrica Scandinavica. 2020;142(6):456\u201366.","journal-title":"Acta psychiatrica Scandinavica"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-08386-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08386-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08386-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:02:16Z","timestamp":1791464536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-026-08386-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8386"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-08386-2","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"22 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol conformed to the Declaration of Helsinki. The study protocol was approved by the Ondokuz May\u0131s University Clinical Research Ethics Committee (OMU KAEK; approval number 2026\/9). Due to the retrospective design and use of anonymized clinical data, informed consent was waived in accordance with institutional regulations.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"764"}}